Compare Aurora Cannabis Inc (ACB) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

AMC trades at $2.59, up 0.78% today, with a bullish technical signal and recent earnings beats. The stock is testing the $3.00 resistance level, supported by record box office performance and improved cash flow trends. However, the company remains unprofitable with a net income margin of -10.59% and high debt levels, though valuation ratios like P/S of 0.28 and P/B of 0.64 suggest potential undervaluation.

Outlook is cautiously optimistic due to strong revenue growth and cost discipline, but risks include persistent losses and heavy debt burden. Analyst consensus price target is $3.00, with 32% buy ratings, indicating moderate upside potential if operational improvements continue.